LONDON, Aug. 10, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that, on August 9, 2018, Dr. David Ebsworth, Chairman of the Company, purchased 12,000 ordinary shares of 5 pence each in the Company (the “Ordinary Shares”) at a price of 120.00 pence per Ordinary Share. Following the acquisition, Dr. Ebsworth will have an interest in the Company of 147,787 Ordinary Shares, representing 0.14% of the Company’s issued share capital.
The notification set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.
The Company also announces that, on August 9, 2018, it issued 58,112 new Ordinary Shares (the “New Ordinary Shares”) following the vesting of restricted stock units held by a former employee, Dr. Ken Newman. Application will be made to the London Stock Exchange for the New Ordinary Shares to be admitted to trading on AIM, with dealings expected to commence on 16 August 2018 (“Admission”). Following Admission, the Company will have a total of 105,075,513 Ordinary Shares in issue each carrying one voting right. The Company does not hold any Ordinary Shares in Treasury. This figure of 105,075,513 Ordinary Shares may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name | David Ebsworth | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Chairman | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | Verona Pharma plc | |||
| b) | LEI | 213800EVI6O6J3TIAL06 | |||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
| a) | Description of the financial instrument, type of instrument | Ordinary Shares of 5 pence each | |||
| Identification code | GB00BYW2KH80 | ||||
| b) | Nature of the transaction | David Ebsworth purchased 12,000 Ordinary Shares | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| 120.00 pence per Ordinary Share | 12,000 Ordinary Shares | ||||
| d) | Aggregated information | N/A | |||
| - Aggregated volume | |||||
| - Price | |||||
| e) | Date of the transaction | 9 August 2018 | |||
| f) | Place of the transaction | London Stock Exchange, AIM | |||
For further information, please contact:
| Verona Pharma plc | Tel: +44 (0)20 3283 4200 |
| Jan-Anders Karlsson, Chief Executive Officer | info@veronapharma.com |
| Stifel Nicolaus Europe Limited (Nominated Adviser and UK Broker) | Tel: +44 (0) 20 7710 7600 |
| Stewart Wallace / Jonathan Senior / Ben Maddison |